{"id":39012,"date":"2023-10-31T08:30:36","date_gmt":"2023-10-31T08:30:36","guid":{"rendered":"https:\/\/prosfunds.com\/investing\/day-one-gets-fda-priority-review-of-tovorafenib-in-pediatric-brain-tumor\/"},"modified":"2023-10-31T08:30:37","modified_gmt":"2023-10-31T08:30:37","slug":"day-one-gets-fda-priority-review-of-tovorafenib-in-pediatric-brain-tumor","status":"publish","type":"post","link":"https:\/\/prosfunds.com\/?p=39012","title":{"rendered":"Day One Gets FDA Priority Review of Tovorafenib in Pediatric Brain Tumor"},"content":{"rendered":"
\n

By Colin Kellaher<\/p>\n

<\/pre>\n
Day One Biopharmaceuticals has won U.S. Food and Drug Administration priority review for its application seeking approval of its lead product candidate tovorafenib in the most common brain tumor diagnosed in children.<\/p>\n
The Brisbane, Calif., clinical-stage biopharmaceutical company on Monday said the application covers tovorafenib as a monotherapy in relapsed or progressive pediatric low-grade glioma.<\/p>\n
\n
The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period.<\/p>\n
Day One said the FDA set a target action date of April 30, 2024, adding that the agency isn’t currently planning to hold an advisory committee meeting to discuss the application.<\/p>\n
<\/pre>\n
Write to Colin Kellaher at colin.kellaher@wsj.com<\/p>\n
<\/pre>\n<\/p><\/div>\n<\/div>\n
Read the full article here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"
By Colin Kellaher Day One Biopharmaceuticals has won U.S. Food and Drug Administration priority review for its application seeking approval of its lead product candidate tovorafenib in the most common brain tumor diagnosed in children. The Brisbane, Calif., clinical-stage biopharmaceutical company on Monday said the application covers tovorafenib as a monotherapy in relapsed or progressive […]<\/p>\n","protected":false},"author":1,"featured_media":3704,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","footnotes":""},"categories":[32],"tags":[],"class_list":{"0":"post-39012","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-investing"},"yoast_head":"\nDay One Gets FDA Priority Review of Tovorafenib in Pediatric Brain Tumor | Prosfunds<\/title>\n<meta name=\"description\" content=\"By Colin Kellaher Day One Biopharmaceuticals has won U.S. Food and Drug Administration priority review for its application seeking approval of its lead\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/prosfunds.com\/?p=39012\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Day One Gets FDA Priority Review of Tovorafenib in Pediatric Brain Tumor | Prosfunds\" \/>\n<meta property=\"og:description\" content=\"By Colin Kellaher Day One Biopharmaceuticals has won U.S. Food and Drug Administration priority review for its application seeking approval of its lead\" \/>\n<meta property=\"og:url\" content=\"https:\/\/prosfunds.com\/?p=39012\" \/>\n<meta property=\"og:site_name\" content=\"Prosfunds\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-31T08:30:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-31T08:30:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/mw_logo_social.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"News Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"News Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/prosfunds.com\/?p=39012#article\",\"isPartOf\":{\"@id\":\"https:\/\/prosfunds.com\/?p=39012\"},\"author\":{\"name\":\"News Room\",\"@id\":\"https:\/\/prosfunds.com\/#\/schema\/person\/bab8f1b00ccebe43e39ff640793108e6\"},\"headline\":\"Day One Gets FDA Priority Review of Tovorafenib in Pediatric Brain Tumor\",\"datePublished\":\"2023-10-31T08:30:36+00:00\",\"dateModified\":\"2023-10-31T08:30:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/prosfunds.com\/?p=39012\"},\"wordCount\":144,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/prosfunds.com\/#organization\"},\"articleSection\":[\"Investing\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/prosfunds.com\/?p=39012#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/prosfunds.com\/?p=39012\",\"url\":\"https:\/\/prosfunds.com\/?p=39012\",\"name\":\"Day One Gets FDA Priority Review of Tovorafenib in Pediatric Brain Tumor | Prosfunds\",\"isPartOf\":{\"@id\":\"https:\/\/prosfunds.com\/#website\"},\"datePublished\":\"2023-10-31T08:30:36+00:00\",\"dateModified\":\"2023-10-31T08:30:37+00:00\",\"description\":\"By Colin Kellaher Day One Biopharmaceuticals has won U.S. Food and Drug Administration priority review for its application seeking approval of its lead\",\"breadcrumb\":{\"@id\":\"https:\/\/prosfunds.com\/?p=39012#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/prosfunds.com\/?p=39012\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/prosfunds.com\/?p=39012#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/prosfunds.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Day One Gets FDA Priority Review of Tovorafenib in Pediatric Brain Tumor\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/prosfunds.com\/#website\",\"url\":\"https:\/\/prosfunds.com\/\",\"name\":\"Funding Factories\",\"description\":\"Latest Finance News and Updates\",\"publisher\":{\"@id\":\"https:\/\/prosfunds.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/prosfunds.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/prosfunds.com\/#organization\",\"name\":\"Funding Factories\",\"url\":\"https:\/\/prosfunds.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/prosfunds.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/ff-dark-logo-1.png\",\"contentUrl\":\"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/ff-dark-logo-1.png\",\"width\":780,\"height\":140,\"caption\":\"Funding Factories\"},\"image\":{\"@id\":\"https:\/\/prosfunds.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/prosfunds.com\/#\/schema\/person\/bab8f1b00ccebe43e39ff640793108e6\",\"name\":\"News Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/prosfunds.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/avatar_user_1_1693518183-96x96.png\",\"contentUrl\":\"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/avatar_user_1_1693518183-96x96.png\",\"caption\":\"News Room\"},\"sameAs\":[\"https:\/\/prosfunds.com\"],\"url\":\"https:\/\/prosfunds.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Day One Gets FDA Priority Review of Tovorafenib in Pediatric Brain Tumor | Prosfunds","description":"By Colin Kellaher Day One Biopharmaceuticals has won U.S. Food and Drug Administration priority review for its application seeking approval of its lead","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/prosfunds.com\/?p=39012","og_locale":"en_US","og_type":"article","og_title":"Day One Gets FDA Priority Review of Tovorafenib in Pediatric Brain Tumor | Prosfunds","og_description":"By Colin Kellaher Day One Biopharmaceuticals has won U.S. Food and Drug Administration priority review for its application seeking approval of its lead","og_url":"https:\/\/prosfunds.com\/?p=39012","og_site_name":"Prosfunds","article_published_time":"2023-10-31T08:30:36+00:00","article_modified_time":"2023-10-31T08:30:37+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/mw_logo_social.png","type":"image\/png"}],"author":"News Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"News Room","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/prosfunds.com\/?p=39012#article","isPartOf":{"@id":"https:\/\/prosfunds.com\/?p=39012"},"author":{"name":"News Room","@id":"https:\/\/prosfunds.com\/#\/schema\/person\/bab8f1b00ccebe43e39ff640793108e6"},"headline":"Day One Gets FDA Priority Review of Tovorafenib in Pediatric Brain Tumor","datePublished":"2023-10-31T08:30:36+00:00","dateModified":"2023-10-31T08:30:37+00:00","mainEntityOfPage":{"@id":"https:\/\/prosfunds.com\/?p=39012"},"wordCount":144,"commentCount":0,"publisher":{"@id":"https:\/\/prosfunds.com\/#organization"},"articleSection":["Investing"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/prosfunds.com\/?p=39012#respond"]}]},{"@type":"WebPage","@id":"https:\/\/prosfunds.com\/?p=39012","url":"https:\/\/prosfunds.com\/?p=39012","name":"Day One Gets FDA Priority Review of Tovorafenib in Pediatric Brain Tumor | Prosfunds","isPartOf":{"@id":"https:\/\/prosfunds.com\/#website"},"datePublished":"2023-10-31T08:30:36+00:00","dateModified":"2023-10-31T08:30:37+00:00","description":"By Colin Kellaher Day One Biopharmaceuticals has won U.S. Food and Drug Administration priority review for its application seeking approval of its lead","breadcrumb":{"@id":"https:\/\/prosfunds.com\/?p=39012#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/prosfunds.com\/?p=39012"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/prosfunds.com\/?p=39012#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/prosfunds.com\/"},{"@type":"ListItem","position":2,"name":"Day One Gets FDA Priority Review of Tovorafenib in Pediatric Brain Tumor"}]},{"@type":"WebSite","@id":"https:\/\/prosfunds.com\/#website","url":"https:\/\/prosfunds.com\/","name":"Funding Factories","description":"Latest Finance News and Updates","publisher":{"@id":"https:\/\/prosfunds.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/prosfunds.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/prosfunds.com\/#organization","name":"Funding Factories","url":"https:\/\/prosfunds.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/prosfunds.com\/#\/schema\/logo\/image\/","url":"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/ff-dark-logo-1.png","contentUrl":"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/ff-dark-logo-1.png","width":780,"height":140,"caption":"Funding Factories"},"image":{"@id":"https:\/\/prosfunds.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/prosfunds.com\/#\/schema\/person\/bab8f1b00ccebe43e39ff640793108e6","name":"News Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/prosfunds.com\/#\/schema\/person\/image\/","url":"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/avatar_user_1_1693518183-96x96.png","contentUrl":"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/avatar_user_1_1693518183-96x96.png","caption":"News Room"},"sameAs":["https:\/\/prosfunds.com"],"url":"https:\/\/prosfunds.com\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/posts\/39012","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/prosfunds.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=39012"}],"version-history":[{"count":1,"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/posts\/39012\/revisions"}],"predecessor-version":[{"id":39013,"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/posts\/39012\/revisions\/39013"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/media\/3704"}],"wp:attachment":[{"href":"https:\/\/prosfunds.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=39012"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/prosfunds.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=39012"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/prosfunds.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=39012"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}